MediGene: Presentation of Clinical Data Obtained with EndoTAG(TM)-1 for the Treatment of Pancreatic Cancer and with the Oncolytic Virus NV1020 for the Treatment of Metastasized Colorectal Carcinoma at

Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------

Martinsried/Munich, January 16, 2008. The biotech company MediGene AG
(Frankfurt, Prime Standard: MDG) announces that the clinical data
obtained with the drug candidate EndoTAG(TM)-1 will be presented at
the ASCO GI (American Society of Clinical Oncology -The
Gastrointestinal Cancers Symposium Meeting) in San Francisco.
Professor Mathias Löhr, principal investigator of the phase II
clinical trial of EndoTAG(TM)-1 for the treatment of inoperable
pancreatic carcinoma, will give a lecture on the results obtained in
this trial, which were published in October 2008. Mathias Löhr is
professor of gastroenterology and hepatology at Karolinska
Institutet, Stockholm, and Head of Molecular Gastroenterology at the
German Cancer Research Center (DKFZ), Heidelberg. The selection of
the EndoTAG(TM)-1 data for presentation at the ASCO GI meeting
illustrates the interest in this drug candidate on the part of
scientists.

The lecture "A phase II trial of cationic liposomal paclitaxel in
combination with gemcitabine in patients with unresectable pancreatic
cancer" will be given in the "Oral Abstract Session: Cancers of the
Pancreas, Small Bowel, and Hepatobiliary Tract" today, January 16,
2009 at 1:15-1:30 pm local time (22.15 CET). In addition, a poster
presentation of the data will be given during the evening session.

Moreover Professor T.R. Reid (University of California, San Diego,
USA) will present further clinical data regarding safety and efficacy
from the trial CT1030 of the oncolytic virus NV1020 in patients with
advanced colorectal cancer metastatic to liver, during a poster
session which will take place on Saturday, January 17, 2009, from
7:00-8:15 am local time. This lecture is titled "Phase II study of an
onkolytic Herpes simplex virus (NV1020) in patients with colorectal
cancer metastatic to liver (mCRC)".

This press release contains forward-looking statements representing
the opinion of MediGene as of the date of this release. The actual
results achieved by MediGene may differ significantly from the
statements made herein. MediGene is not bound to update any of these
forward-looking statements. MediGene® and EndoTAG(TM)-1 are
registered trademarks of MediGene AG. These trademarks may be owned
or licensed in select locations only.

- ends -

MediGene AG is a publicly listed (Frankfurt, Prime Standard: MDG)
biotechnology company located in Martinsried/Munich, Germany, with
subsidiaries in Oxford, UK and San Diego, USA. MediGene is the first
German biotech company to have drugs on the market, which are being
distributed by partner companies. MediGene has several drug
candidates in clinical development, including EndoTAG(TM)-1, which
could offer substantial sales returns. In addition, the company has
numerous projects in research and pre-clinical development and
possesses innovative platform technologies. MediGene focuses on the
research and development of novel drugs for the treatment of cancer
and autoimmune diseases.

Contact MediGene AG
E-mail: investor@medigene.com
Fax:+49 - 89 - 85 65 - 2920
Julia Hofmann / Dr. Nadja Wolf, Public Relations, Tel.: +49 - 89 - 85
65 - 3324
Dr. Georg Dönges, Investor Relations, Tel.: +49 - 89 - 85 65 - 2946

--- End of Message ---

MediGene AG
Lochhamer Strasse 11 Martinsried / München Germany

WKN:
502090; ISIN: DE0005020903 ;
Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in
Bayerische Börse München,
Freiverkehr in Börse Düsseldorf, Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr
in Niedersächsische Börse zu Hannover,
Geregelter Markt in Frankfurter Wertpapierbörse;
Copyright © Hugin AS 2009. All rights reserved.